You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-CDKN1A (CDKN1A) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 1A Antibodies (CDKN1A)
On are 4 Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) Antibodies from 2 different suppliers available. Additionally we are shipping CDKN1A Kits (10) and CDKN1A Proteins (3) and many more products for this protein. A total of 17 CDKN1A products are currently listed.
CAP20, CDKI, Cdkn1, CIP1, MDA-6, mda6, P21, p21Cip1, p21WAF, SDI1, Waf1
list all antibodies Gene Name GeneID UniProt
CDKN1A 1026 P38936
Anti-Mouse CDKN1A CDKN1A 12575 P39689

Show all species

Show all synonyms

Most Popular Reactivities for anti-CDKN1A (CDKN1A) Antibodies

Select your species and application

anti-Human CDKN1A Antibodies:

anti-Rat (Rattus) CDKN1A Antibodies:

All available anti-CDKN1A Antibodies

Go to our pre-filtered search.

More Antibodies against CDKN1A Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) interaction partners

  1. These data reveal a novel role for p21/waf1 in the resolution of inflammation via its ability to control neutrophil apoptosis.

  2. role of SRSF7 (show SFRS7 Antibodies) in cell proliferation through regulating p21 levels.

  3. Data indicate that UBE2S and APC3 co-regulate the expression level of P21 at G2/M check point via the ubiquitin-proteasome system.

  4. p53 (show TP53 Antibodies)/p21 signaling pathway role in melanoma cells

  5. The expression of p53 fulllength transcript and Delta133p53 isoforms alpha, beta and gamma transcripts, MDM2 and p21 transcripts were determined by reverse transcriptionquantitative polymerase chain reaction, in total RNA isolated from 17 lung carcinoma specimens and 17 corresponding adjacent noncancerous tissues.

  6. CDKN1A (p21) was identified as a functional target of miR (show MLXIP Antibodies)-33b-3p, a critical regulator of G1/S checkpoint, which potentially mediated the protection effects of miR (show MLXIP Antibodies)-33b-3p against cisplatin.

  7. Ectopic expression of the CDK (show CDK4 Antibodies) inhibitor p21(Cip1) enhanced deregulated E2F (show E2F1 Antibodies) activity and pro-apoptotic E2F (show E2F1 Antibodies) target gene expression in cancer cells. Moreover, ectopic expression of p21(Cip1) augmented cancer specific cytotoxicity of Ad-ARF (show CDKN2A Antibodies)-TK, and apoptosis induced by p21(Cip1) was dependent on deregulated E2F (show E2F1 Antibodies) activity.

  8. We also showed that knockdown of urothelial carcinoma-associated 1 increased the p21 protein (show NRAS Antibodies) expression through regulating enhancer of zeste homolog 2 (show EZH2 Antibodies). In addition, bioinformatics analysis and dual-luciferase reporter assays confirmed that miR (show MLXIP Antibodies)-495 was a target of urothelial carcinoma-associated 1 in renal cell carcinoma (show MOK Antibodies), and urothelial carcinoma-associated 1 promoted cell proliferation by negatively regulating miR (show MLXIP Antibodies)-495

  9. reveal the tumour-promoting ability of p21 through deregulation of DNA replication licensing machinery-an unorthodox role to be considered in cancer treatment

  10. data demonstrate that DDX41 (show DDX41 Antibodies) suppresses p21 translation without disturbing the function of p53 (show TP53 Antibodies) to directly induce p21 mRNA expression, this process indirectly requires p53 (show TP53 Antibodies), perhaps in the form of another p53 (show TP53 Antibodies) target gene or as a still undefined posttranscriptional function of p53 (show TP53 Antibodies).

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) interaction partners

  1. These data reveal a novel role for p21/waf1 in the resolution of inflammation via its ability to control neutrophil apoptosis.

  2. the silencing of Cyclin-dependent kinase 5 (show CDK5 Antibodies) preventing memory dysfunction

  3. Results show that p21 (show D4S234E Antibodies) expression is regulated by OLA1 (show OLA1 Antibodies) to promote cell proliferation and organogenesis.

  4. AS160 (show TBC1D4 Antibodies) regulates glucose-independent eukaryotic cell proliferation through p21 (show D4S234E Antibodies)-dependent control of the cell cycle.

  5. telomerase activity and cardiomyocyte telomere length decrease sharply in wild-type mouse hearts after birth, resulting in cardiomyocytes with dysfunctional telomeres and anaphase bridges and positive for the cell-cycle arrest protein p21 (show D4S234E Antibodies).

  6. Consistent with the latter, Arid1a (show ARID1A Antibodies) reexpression in tumor cells led to increased p21 (Cdkn1a) expression and dramatic accumulation of cells in G2 phase of the cell cycle. These results also indicate a potential opportunity for therapeutic intervention in ARID1A (show ARID1A Antibodies)-deficient human breast cancer subtypes that retain one intact copy of the gene and also maintain wild-type TRP53 (show TP53 Antibodies) activity

  7. We discovered that FXR1P (show FXR1 Antibodies)-deficient aNSCs have altered expression of a select number of cell-cycle genes, and we identified the mRNA of cyclin-dependent kinase inhibitor 1A (Cdkn1a, p21 (show D4S234E Antibodies)) as a direct target of FXR1P (show FXR1 Antibodies).

  8. These results demonstrate that CQ and AQ increase the expression level of p21 (show D4S234E Antibodies) and inhibit T cell proliferation and the development of IFN-gamma (show IFNG Antibodies)-producing Th1 (show HAND1 Antibodies) cells, thereby revealing beneficial roles in treating a wide range of chronic inflammatory diseases mediated by inflammatory T cells.

  9. increases the number of ALP (show CCL21A Antibodies)-positive colonies after iPSC induction and decreases expression levels of Eomes (show EOMES Antibodies) and p21 (show D4S234E Antibodies) mRNAs. Based on these observations, we propose that the CCR4 (show CCR4 Antibodies)-NOT deadenylase activity contributes to iPSC induction.

  10. this study shows that p21 (show D4S234E Antibodies) is upregulated in T effector cells but not natural regulatory T cells after treatment with azacitidine, which protects from graft-versus-host Disease

CDKN1A Antigen Profile

Antigen Summary

This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.

Alternative names and synonyms associated with CDKN1A

  • cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) antibody
  • cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a) antibody
  • CAP20 antibody
  • CDKI antibody
  • Cdkn1 antibody
  • CIP1 antibody
  • MDA-6 antibody
  • mda6 antibody
  • P21 antibody
  • p21Cip1 antibody
  • p21WAF antibody
  • SDI1 antibody
  • Waf1 antibody

Protein level used designations for CDKN1A

CDK-interacting protein 1 , CDK-interaction protein 1 , DNA synthesis inhibitor , cyclin-dependent kinase inhibitor 1 , melanoma differentiation associated protein 6 , wild-type p53-activated fragment 1 , melanoma differentiation-associated protein , p21

1026 Homo sapiens
12575 Mus musculus
Selected quality suppliers for anti-CDKN1A (CDKN1A) Antibodies
Did you look for something else?